Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8 þ T cells as well as CD4 þ CD25 þ FoxP3 þ regulatory T cells toward an antileukemia response Recently, we described that vaccination with allogeneic dendritic cells (DCs) pulsed with tumor cell lysate generated specific CD8 þ T cell response in patients with B-cell chronic lymphocytic leukemia (B-CLL). In the present study, the potential of autologous DCs pulsed ex vivo with tumor cell lysates to stimulate antitumor immunity in patients with B-CLL in early stages was evaluated. Twelve patients at clinical stage 0-2 as per Rai were vaccinated intradermally up to eight times with a mean number of 7.4 Â 10 6 DCs pulsed with B-CLL cell lysate. We observed a decrease of peripheral blood leukocytes and CD19 þ /CD5 þ leukemic cells in five patients, three patients showed a stable disease and four patients progressed despite DC vaccination. A significant increase of specific cytotoxic CD8 þ T lymphocytes against the leukemia-associated antigens RHAMM or fibromodulin was detected in four patients after DC vaccination. In patients with a clinical response, an increase of interleukin 12 (IL-12) serum levels and a decrease of the frequency of CD4 þ CD25 þ FOXP3 þ T regulatory cells were observed. Taken together, the study demonstrated that vaccination with autologous DC in CLL patients is feasible and safe. Immunological and to some extend hematological responses could be noted, justifying further investigation on this immunotherapeutical approach.
Introduction
B-cell chronic lymphocytic leukemia (B-CLL) is the most common leukemia of adults in Western countries. Treatment regimens with purine nucleoside analogues and monoclonal antibodies (mAb) have increased the rate of molecular complete remissions and may result in a longer time to progression. [1] [2] [3] However, these options bear significant risks for infectious complications, which must be carefully weighted against the risks by the underlying disease. 4, 5 Allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapy for B-CLL, 6, 7 but due to the high treatment-related mortality and advanced age of most patients, the procedure is not applicable for the majority of B-CLL patients. Therefore, there is a fervent need for novel therapeutic strategies. Some clinical observations, such as positive responses of immunomodulatory cytokines, 8 the existence of a graft-vs-leukemia effect after allogeneic HCT, 9 indicate a T cell-mediated antileukemic effect to CLL cells. B-CLL is a very attractive disease to be targeted by immunotherapy due to its rather low progression and due to the availability of cancer cells in the peripheral blood (PB). Dendritic cells (DCs) are the most professional antigen-presenting cells (APCs), but are deficient in B-CLL. 10, 11 Therefore, administration of ex vivo generated DCs might improve the antileukemic T-cell response in patients with B-CLL. Our group reported the first clinical trial with allogeneic DCs stimulated with leukemic cells lysates in B-CLL patients. 12 Immunological and to some extend clinical responses were noted. To answer the question whether autologous DCs might cause a similar immunotherapeutical effect we conducted the present study assessing the safety and feasibility as well as the clinical and immunological responses to autologous DC immunotherapy in B-CLL patients. Specific CD8 þ T-cell responses to RHAMM, survivin, fibromodulinFrecently described as tumor-specific antigens (TAAs) in B-CLLFwere evaluated by multiparametric tetramer-based flow cytometry and enzyme-linked immunosorbent spot (ELISPOT) assays. Furthermore, the percentage of CD4 þ CD25 þ FoxP3 þ T-regulatory cells in the PB over the time of vaccination was assessed.
Materials and methods

Patients
Twelve patients were enrolled into the study (four female and eight male patients) aged between 47 and 70 years (mean 58 years). All 12 patients were diagnosed with B-CLL at early stages (Rai 0-2), and all except one (patient 4) were therapy naive. In patient 4, the last dose of chemotherapy (2-chlorodeoxyadenosine/cladribine and cyclophosphamide) had been administered 13 months before the start of DC immunotherapy. Patients were eligible for vaccination if they had (1) an Eastern Cooperative Oncology Group score o2, (2) hepatic and renal functions not exceeding the threefold of the upper limit of normal values, (3) not received any immunosuppressive drugs and (4) no autoimmune disease and a life expectancy of more than 6 months. Exclusion criteria were (1) severe heart, lung or other systemic diseases; (2) acute infections requiring active treatment and (3) a prior history of other malignancies. The clinical protocol was approved by the local ethics committee (KE-0254/18/2002), and all patients gave their written informed consent for the DC vaccination after we discussed with them that DC vaccination constitutes an option to the 'watch and wait' strategy as standard procedure. The characteristics of the patients are summarized in Table 1 .
Isolation of monocytes as precursors of dendritic cells
Precursor cells for the generation of monocyte-derived DCs were obtained by two different methods. In patients 1 and 2, DCs were generated from the adherent fraction of peripheral blood mononuclear cells (PBMC) from the leukapheresis products. In the other patients, precursor cells were obtained from 150 ml of PB taken by venipuncture. Monocytes were then purified by positive selection of CD14 þ cells (patients 3-12).
Preparation of autologous DC precursors from leukapheresis products of B-CLL patients
Peripheral blood mononuclear cells were isolated from leukocyte-enriched leukapheresis products by density gradient centrifugation (Gradisol-L, Aqua Medica, Lodz, Poland). The percentage of CD14 þ monocytes in the leukapheresis products was 3.02% (range 0.86-8.46%) and the monocyte yield was 9.19 Â 10 8 . After isolation, the cells were washed twice with phosphate-buffered saline (PBS) and seeded into three-level cell culture flasks (Cell Factory, Nunc, Roskilde, Denmark) in RPMI 1640 medium (BioWhittaker, Walkersville, MD, USA) containing 2% human albumin, 1% of L-glutamine and 1% of penicillin/streptomycin for 2 h in 37 1C and 5% CO 2 . After incubation, the nonadherent cells were removed and were lysed to obtain leukemic cell lysates.
Preparation of autologous DC precursors from the peripheral blood of B-CLL patients
Peripheral blood mononuclear cells were isolated from 150 ml heparinized PB samples by density gradient centrifugation (Gradisol-L, Aqua Medica). After isolation, the cells were washed twice with PBS and incubated with anti-CD14 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and passed through magnetic cell separation (MACS) columns according to the manufacturer's protocols. The CD14À cell population was used to prepare lysates of leukemic cells.
Preparation of the leukemic cell lysates
A total of 10 8 CD14À cells were isolated from the PB of the respective patient and homogenized in five repeated cycles of freezing at À80 1C and subsequent thawing. Supernatants were passed through a 0.2 mm millipore filter and aliquots were stored at À80 1C until use.
Generation of autologous dendritic cells
The adherent cells were cultured in the appropriate tissue culture medium containing RPMI 1640 supplemented with 1% human albumin (ZLB Bioplasma AG, Bern, Switzerland), 100 IU ml À1 penicillin, 50 mg ml À1 streptomycin and 100 mg ml À1 neomycin. On days 1, 3 and 5 of the culture 1000 IU ml À1 rhGM-CSF (Leukine, Berlex, Richmond, CA, USA) and 50 ng ml À1 rhIL-4 (Strathmann, Hannover, Germany) were added. Tumor necrosis factor-a (TNFa) at a concentration of 10ngml À1 and the lysates from 10 8 leukemic cells were added during the last 48 h of culture for the maturation and pulsing of the DC. On day 8 of culture, DCs were harvested using trypsin/EDTA solution, washed twice in 0.9% NaCl and resuspended in 1 ml of 0.9% NaCl. Their viability was checked by Trypan blue staining in light microscopy. Flow cytometry analysis was performed using mouse mAb against CD80, CD86, CD83, CD1a and human leukocyte antigens (HLA)-DR, all purchased from Caltag Laboratories (Burlingame, CA, USA). The vaccine product was prepared immediately before each vaccination.
Treatment schedule
A vaccination course consisted of 5-8 injections of autologous DCs stimulated with tumor lysates. Patients 1 and 2 received five injections of DC at four weekly intervals. The other patients (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) received eight vaccinations, their first four injections were administered at biweekly intervals and the following vaccinations at four weekly intervals. DC vaccines were injected intradermally in the close vicinity of axillar and inguinal lymph nodes.
Evaluation of the clinical response to and the toxicity of the DC vaccination
Patients were checked before each vaccination as by physical examination, differential blood count and serum chemistry. These examinations were repeated before administration of each vaccination and during follow-up examinations every 3 months for 12 months. A decrease of the white blood cell (WBC) count for more than 25% of the initial value was considered as a clinical response/hematological improvement. All patients were monitored for local and systemic toxicity according to the grading system of the National Cancer InstituteFCommon Toxicity Criteria (NCI-CTC).
Evaluation of the immune response to the DC vaccination
The immune response was evaluated by immunophenotyping subsets of the PB lymphocytes and by assays for T-cell proliferation, serum cytokine concentration, phagocytic function of monocyte-derived DCs, specific response of autologous T cells to selected TAAs by ELISPOT and tetramer staining.
Analysis of peripheral blood lymphocyte subsets
The expression of the cell-surface antigens CD14/CD45, CD3/ CD19/CD69, CD3/CD19/CD25, CD3/CD19/CD95, CD4/CD8/ CD69, CD4/CD8/CD25, CD4/CD8/CD95, CD5/CD19/CD95 was determined for each patient's lymphocyte population (Caltag Laboratories). The samples were measured using the FACS Calibur cytometer (Becton Dickinson, San Jose, CA, USA) and the data were analyzed by the CellQuest software (Becton Dickinson).
Analysis of T-regulatory cells
T regulatory cells in the PB of vaccinated B-CLL patients were evaluated by the surface expression of the cell-surface antigens CD4 þ and CD25 þ as well as intracellular expression of the FoxP3 by flow cytometry (FACS Calibur). The percentage of CD4 þ CD25 þ FoxP3 þ regulatory T cells (Treg) in CD4 þ lymphocytes was determined by using the Human Treg Flow Kit (FOXP3 Alexa Fluor 488/CD4 PECy5/CD25 PE) from BioLegend (San Diego, CA, USA). (10-12/ 2003) , the last course of CP was given 13 months prior to DC immunotherapy; RS, defined as a 425% decrease in lymphocytes after DC vaccination.
Proliferation assay
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Leukemia cultured without addition of DCs or lysates were used as negative control. CD3 þ cells stimulated with phorbol 13-myristate 12-acetate (Sigma-Aldrich, Seelze, Germany) were used as positive control. 
Measurement of cytokine concentration
Serum samples were collected and stored at À80 1C. The concentration of interleukin 2 (IL-2), IL-4, IL-10, TNFa and IL-12 in the serum was measured using enzyme-linked immunosorbent assays (Bender MedSytems, Vienna, Austria) and ELx800 (Bio-Tek Instrumental Inc., Winooski, VT, USA), according to the manufacturer's instructions.
HLA-A2 typing
All patients were tested for HLA-A2 expression using fluorescence-activated cell sorting (FACS) analysis with an mAb specific for HLA-A2 (Clone BB7.2, BD Biosciences, Heidelberg, Germany) as only T-cell epitopes restricted to this HLA type have been described for CLL-associated TAAs.
mRNA preparation and PCR mRNA was prepared from the PBMC of the CLL patients, transcribed to cDNA and subjected to PCR to test the expression of selected TAAs as described earlier. 13 The PCR products were then separated by agarose gel electrophoresis and visualized with ethidium bromide using UV light.
Mixed lymphocyte peptide culture
Peripheral blood mononuclear cells from B-CLL patients taken after every second vaccination were separated by Ficoll and subsequently selected by anti-CD8 microbeads through a CD8 þ MACS column and subjected to one round of mixed lymphocyte peptide culture (MLPC) as described earlier. 13, 14 On the basis of previous studies by others 15, 16 and our own group, 13, 14 we used the RHAMM-derived HLA-A2-restricted CD8 þ T-cell epitope R3 (position 165-173: ILSLELMKL), fibromodulin (FMOD)-derived (position 250-259: YMEHNN-VYTV) and survivin-derived (position 97-106: ELTLGEFLKL). This particular FMOD peptide sequence was chosen as it showed a superior immunogenicity when compared to the three other peptides described by Mayr et al. 17 The influenza matrix protein (IMP)-derived peptide (GILGFVFTL) was used as a positive control, the melanoma antigen-derived peptide (FLWGPRALV) as an irrelevant peptide, that is, negative control.
IFN-g and granzyme B ELISPOT assay
Interferon-g (IFN-g) and granzyme B ELISPOT assays were performed as described earlier, 14, 15 to determine the TAA peptide-specific activation and lytic potential of the patients' CD8 þ T cells before and after DC vaccination.
Tetramer staining
The frequency of peptide-specific CD8 þ T lymphocytes was determined after 2 weeks of MLPC by staining with anti-CD8 antibody and HLA-A2-peptide-specific tetramer Â phycoerythrin (PE) (courtesy of Immanuel Luescher and Philippe Guillaume, LICR, Lausanne, Switzerland). CD8 þ T lymphocytes (0.5-1 Â 10 6 ) stimulated with irradiated CD8À APCs in the presence of the specific peptide were stained with HLA-A2-specific peptide tetramer Â PE and with HLA-A2/WT1 peptide tetramer Â PerCP 1 ml per test with respect to the peptide-major histocompatibility complex class I component in the dark and incubated for 40 min at room temperature. Thereafter, 5 ml CD8 Â APC-Alexa Fluor (Invitrogen, CA, USA; Caltag Laboratories), 5 ml CD45RA Â APC (Invitrogen, Caltag Laboratories), 10 ml CCR7 Â PE-Cy7 (BD Biosciences) and 10 ml CD27 Â FITC (BD Biosciences) were added for 20 min at 4 1C in the dark. After washing once with PBS, stained cells were fixed with 1% formaldehyde (Sigma-Aldrich) and acquired in a FACS Calibur flow cytometer. The data were analyzed using CellQuest software. In all cases at least 100 000 events were collected for analysis. Each sample was run with an appropriate isotype control and this was used to define the gate of positive cells. Analysis was performed on tightly gated lymphocytes to exclude dead cells and debris and on CD8 þ T lymphocytes to evaluate responses to specific peptide. Samples were defined as positive only if at least 0.03% of CD8 þ T lymphocytes showed tetramer staining.
Results
Vaccine preparation
With both methods to collect precursor cells in this study, 7-day cultures of monocytes in the cytokine-supplemented media resulted in the generation of cells with a characteristic appearance for mature DCs in light microscopy (data not shown). As assessed by flow cytometry analysis, the cells harvested on day 8 showed a typical phenotype of mature DCs, expressing HLA-DR (99±8%), CD83 (98±58%), CD86 (87 ± 15%), CD80 (98 ± 9%) and CD1a (57 ± 30%). Figure 1 displays representative results from the immunophenotyping of cells prepared by the two different collection strategies. However, significant differences in the percentage of DCs defined as CD83 þ CD80 þ CD86 þ cells and contaminating lymphocytes were seen for the different cell collection strategies as displayed in Table 2 . To assess the function of the DCs, we measured the phagocytosis of the cells as engulfment of FITClabeled dextran particles. The engulfment was 480% for both preparations after 24 h, with the best results obtained by CD14 positive selection.
Clinical responses
The clinical outcome of the patients was defined as follows: patients who showed a 25% or higher reduction in their WBC count after vaccination were considered responders (RS), patients with less than 25% reduction of their WBC count showed a stable disease (SD) and patients with an increase of Vaccination of B-CLL patients with autologous dendritic cells I Hus et al their WBC count higher than 25% of their value before vaccination were scored nonresponders (NR). All the patients completed the treatment schedule. A clinical response was observed in five patients (1, 2, 5, 6, 7; RS), and a stable disease in three patients (8, 10, 11 ; stable disease group, SD). Four patients did not respond to DC therapy (3, 4, 9, 12; NR). The best clinical response was observed in the patients treated with DCs generated from adherent fraction of PBMC obtained by leukapheresis (patients 1 and 2). In these patients the substantial decrease of WBC and lymphocytes count was maintained after the end of DC therapy, in patient 1 even the normalization of WBC count occurred 6 months after the end of treatment (WBC 9.2 G/l, lymphocytes 6.5 G/l ). These decreased WBC values still remain on the same level at 41 months after the end of the therapy, while in the other patients a decrease of the WBC count was observed mainly for 4 months of the vaccination period. Trend curves of WBC and PB lymphocytes of patients 1, 10 and 3 are presented in Figure 2 . No correlation was found between the clinical response and the number of DCs in the vaccine preparation. In the RS and SD groups, the mean number of DCs in the vaccine was 6.24±4.70 Â 10 6 and in NR group 6.044 ± 5.84 Â 10 6 . We did not observe any significant changes of red blood cell (RBC), platelet (PLT) or granulocyte count during the period of DC vaccination.
Immunotherapy with autologous DC vaccines was safe and well tolerated. We did not observe any systemic adverse events, only a mild local skin reaction (NCI-CTC v. 3.0 toxicityp1) at the injection site resolving within 2-3 days. During the followup period (median 27 months, range 19-43 months) no other adverse events occurred.
Immunological responses to the vaccine therapy
To screen the overall immune response to our vaccination therapy, we assessed cytokine levels in the serum of the patients before and after DC vaccination. There was a significant increase of IL-12 serum concentrations after DC vaccination when compared with the values before immunotherapy (12 ± 9 vs 6±7 pg ml À1 , P ¼ 0.02, Mann-Whitney's U-test). During the whole immunotherapy period, the serum concentration of IL-12 was significantly higher in the RS and SD groups in comparison to the NR group (10 ± 4 vs 5 ± 2 pg ml À1 , P ¼ 0.025, Mann-Whitney's U-test). In the NR group, IL-12 serum levels decreased significantly during DC vaccination (5 ± 3 vs 2 ± 2 pg ml À1 P ¼ 0.04, Mann-Whitney's U-test). There were no significant changes in the serum concentration of IL-2, IL-4, IL-10 and TNFa before and after immunotherapy.
To further assess the T-cell response to DC vaccination, we performed proliferation assays. No significant differences were found either in the uptake of titrated 3 H-thymidine by T cells when adding immature DCs, or in the ability of the stimulation of autologous T-cell proliferation by mature DCs depending on the method of precursor cell collection (data not shown), but we observed differences in the results of the proliferation assays depending on the response to immunotherapy (Figure 3 In the RS and SD groups, we detected a significant increase of c.p.m. after the end of therapy comparing to the initial values. On the opposite, in NR group, the proliferation of unstimulated as well as stimulated T cells was lower than before immunotherapy (Figure 3) . For a better characterization of T-cell subsets, we performed flow cytometry analysis of lymphocyte subpopulations in the PB of B-CLL patients treated with DC therapy. The results showed a significantly higher percentage of CD3 þ T cells in the RS and SD groups (29 ± 33 vs 5 ± 2%, Po0.001, Mann-Whitney's U-test; data not shown) during the immunotherapy period. Similar observations were made for other T-cell subsets. The percentage of CD4 þ , CD8 þ and natural killer cells as well as the CD4 þ /CD8 þ ratio were significantly higher in RS and SD groups when compared to the NR group (data not shown). On the opposite, the frequencies of CD4 þ CD25 þ , CD4 þ CD95 þ and CD8 þ CD95 þ cells were significantly higher in the NR group when compared with the RS and SD groups: 42 ± 21 vs 16 ± 13%, Po0.001; 54±30 vs 13±14%, Po0.001; 20±15 vs 10±15%, P ¼ 0.001, respectively. There were no significant changes in PB lymphocyte percentage during DC immunotherapy. However, in patients with the most favorable clinical response (1 and 2) we observed a substantial decrease of CD4 þ CD25 þ cells (from 29 ± 12 to 14 ± 11%) and an increase of CD8 þ CD25 þ cells after DC therapy (from 9 ± 2 to 49 ± 56%).
Specific T-cell responses to selected TAAs were evaluated in the patients showing an expression of these antigens and 
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HLA-A2 (Table 3) . We used ELISPOT assays for IFN-g and granzyme B to evaluate the frequency of autologous T cells that were stimulated by TAAs before and during DC vaccinations. In patients with expression of both RHAMM and fibromodulin, specific cytotoxic T lymphocyte (CTL) responses were observed (Table 3 ; Figure 4 ). In patient 4 (NR group), an increase of CTLs was observed after the second dose of DC vaccine, but thereafter decreased below initial values, in accordance with results obtained for T-cell proliferation. In patient 8 with stable disease, we detected an increase of CTLs to RHAMM and fibromodulin after 4, 6 and 8 doses of the vaccine. Among the four patients with fibromodulin expression, in two patients (6 and 7) an increase of CTL was observed after the fourth and sixth DC vaccination, both patients showed a clinical response to the immunotherapy. In patient 10 (SD group) we detected a response only to IMP. Figure 4 displays the results from an FACS analysis of CTL responses to RHAMM and to fibromodulin using tetramer staining in patient 4 before the therapy and after the second vaccine (panel a) as well as the evaluation of CTL responses to RHAMM, fibromodulin and IMP during DC immunotherapy in patients 4 and 8 using both tetramer staining and ELISPOT assays (panels b and c). CD4 þ CD25 þ FoxP3 þ Treg cells can inhibit the function of CD8 þ T cells in cancer patients. In this study, the frequency of Tregs in the PB was measured in 10 patients before and after DC therapy ( Figure 5 ). The percentage of Treg cells dropped in all patients with responsive or stable disease (RS and SD). In contrast, the percentage of Treg cells increased in patients with progressive disease (PD) after DC immunotherapy ( Figure 5 ). The initial frequencies of Treg cells were comparable in all patients (median ¼ 7.1%, range 4.2-9.1%).
Discussion
Dendritic cell vaccines have been evaluated in phase I-III clinical trials for patients with various solid tumors such as melanoma, [18] [19] [20] prostate cancer, 21, 22 renal cell carcinoma [23] [24] [25] and lymphoma. 26, 27 Immunological and also clinical responses observed in these patients prompted researchers in the field to extend the concept of DC vaccination also to leukemia patients. [28] [29] [30] [31] In our previous study with B-CLL patients, 12 we showed that immune and to some extent clinical responses could be achieved in B-CLL patients using allogeneic DCs as anticancer vaccine. Since DC precursor cells were obtained from HLAunmatched donors, one might speculate whether immune and clinical responses in the vaccinated patients might have been related to a specific antigen recognition or rather to an unspecific allo-reaction.
In the present study with autologous DCs where per se all patients received HLA-matched DCs, we particularly aimed at defining antigen-specific T-cell responses to leukemia cells. Using autologous DCs in vaccine protocols for B-CLL patients would be most preferable, taking into account difficulties with identifying an HLA-matched donor and the potential risk of (viral) infection connected with allogeneic DC vaccines. Finally, the search for an HLA-identical donor is time consuming and cost intensive.
In this study we used autologous, monocyte-derived DCs that were generated in classical, 32, 33 7-day cultures with granulocyte monocyte colony-stimulating factor (GM-CSF) and IL-4, as well as TNFa added later on for final maturation. 30 Two methods for the collection of precursor cells were used in the present study. In the first two patients (1 and 2), DCs were generated from the adherent fraction of PBMC obtained by leukapheresis. This rather inexpensive method allows a DC production in healthy subjects, 12 as well as in patients with solid tumors, 18, 34 multiple myeloma 35, 36 and acute myeloid leukemia. 30 However, by this method the amount of DCs was only sufficient for a single vaccine preparation, and leukapheresis had to be performed before each vaccination. Most likely, the low yield of generated DCs resulted from the inhibitory effect of leukemic B cells contaminating cell cultures. 37, 38 The decreased number of circulating monocytes in B-CLL patients might constitute another important issue. In their recent paper, Kokhaei et al. 39 showed that an adequate number of functional DCs required for clinical therapy can be generated only from B-CLL patients who Table 3 Evaluation of specific CTLs to selected TAAs in patients with B-CLL treated with autologous DC vaccinations After II vacc.
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After IV vacc.
After VI vacc.
After VIII vac. analysis demonstrating an increase of CD8 þ cytotoxic T lymphocytes (CTLs) specific to the tumor/leukemia-associated antigens RHAMM and fibromodulin (FMOD) after the second DC vaccination (12.9 and 4.32%, respectively) as compared to the values before the therapy (3.3 and 2.19%, respectively) in patient 4 with progressive disease as assessed by tetramer staining. However, the enhanced frequency of tetramer-stained CTLs specific for RHAMM or FMOD decreased already after the second vaccination (b, left), in contrast to patient 8 with stable disease, where the enhanced frequency of CTLs specific for RHAMM and FMOD persisted longer; IMP (influenza matrix protein) served as a control antigen. The increase of the CTL responses to the antigens RHAMM and FMOD as well as IMP during autologous DC immunotherapy in patient 8 with stable disease was also confirmed by ELISPOT assays for the secretion of interferon-g (IFNg) and granzyme B by autologous T cells.
have41% of CD14 þ monocytes in the leukapheresis product. In our leukapheresis products, the mean percentage of CD14 þ monocytes was 3% with a range from 1 to 8%.
To improve the yield of DCs from appropriate precursor cells, we isolated monocytes of the PB taken by venipuncture from the 10 following patients (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) , leukemic cells were therefore removed through positive selection of CD14 þ cells resulting in the generation of a number of DCs from 150 ml of PB that was comparable to the DC yield obtained from one leukapheresis procedure. Evaluation of immune responses induced by autologous DC vaccines was a secondary objective of this study. In a first screening, we assessed type 1 and type 2 cytokines in the serum of the patients before and after DC vaccination to evaluate an immune response to the treatment. The serum concentration of the type 1 cytokine IL-12 increased in clinically responding patients and patients with stable disease. In contrast, we observed a decrease of the IL-12 serum level in nonresponders. The serum levels of other cytokines we assessed such as IL-2, IL-4, IL-10 and TNFa remained stable after vaccination. In our patients, the increase of IL-12 serum concentration without observation of an increase of other type 1 cytokines might therefore be interpreted rather as an enhancement of DC function than T-cell activation. IL-12 is one of the most important factors polarizing the immune response toward Th1. 40 In murine studies, the increase of IL-12 production correlated with a reduction of the tumor mass. 41 The immune response due to DC immunotherapy was further evaluated by T-cell proliferation assays. In patients with hematological improvement or stable disease, we observed a continuously increasing proliferation of T cells when stimulated with lysate pulsed DCs in proliferation assays. In contrast, T-cell proliferation to the stimulus DC plus lysate was only transient in patients with PD. Moreover, T cells from the PB of patients with hematological improvement responded also when stimulated with the lysate alone. This suggests that these T cells had been already successfully activated through DC vaccination in vivo. A similar increase of proliferating T cells during DC vaccinations has also been reported for patients with prostate cancer, solid tumors and acute myeloid leukemia. [42] [43] [44] Fluorescence-activated cell sorting analysis of PB lymphocyte populations before and during immunotherapy demonstrated that the percentage of CD3 þ cells as well as CD4 þ and CD8 þ T lymphocytes was significantly higher in patients with clinical response and stable disease comparing to the patients, who did not respond to the therapy. These observations seem to confirm the hypothesis of Wierda et al., 45 suggesting the key role of the immunocompetence of the patients for positive results of immunotherapy in B-CLL patients. We also observed differences in other lymphocyte subsets depending on the type of clinical response. The percentage of CD4 þ CD95 þ and CD8 þ CD95 þ T cells was significantly higher in the nonresponder group when compared to patients with clinical response or stable disease, which might indicate that T cells in nonresponding patients were more prone to apoptosis. According to De Fanis et al. and Tinhofer et al. the susceptibility to apoptosis was connected with a more advanced stage of the disease. 46, 47 In two patients with hematological improvement (patients 1 and 2) a substantial increase of CD8 þ CD25 þ T cells was seen. An increase of T cells expressing CD25 þ indicates an upregulation of T cells responsive to IL-2, which is one of the main cytokines stimulating CD8 þ cell proliferation. Mutis et al. 48 showed that in patients undergoing donor leukocyte infusion after allo-PBSCT, elevated frequencies of infused CD8 þ CD25 þ T cells were accompanied not only with a graft-vs-host disease effect, but also with a graft-vs-tumor effect and complete remissions. In nonresponders the percentage of CD4 þ CD25 þ was significantly higher when compared with patients with hematological improvement or stable disease. The CD4 þ CD25 þ cell subpopulation includes Treg cells that hamper the antileukemic immune response. 49 In our study, the frequency of CD4 þ CD25 þ FoxP3 þ Treg cells among CD4 þ lymphocytes was similar to the Treg frequency described by Dannull et al. 50 in renal cell carcinoma patients (3-5%). According to Dannull et al. 50 the results of DC therapy could be substantially improved by selective elimination of CD4 þ CD25 þ cell populations using danileukin difitox.
For further characterization of the T-cell responses, we performed ELISPOT assays and tetramer-based flow cytometric assays to detect TAA recognition by specific T cells. An increase of production of IFNg and granzyme B by tetramer þ CD8 þ T lymphocytes upon stimulation with respective TAA-derived epitope peptides was determined after DC vaccination of HLA-A2-positive patients. However, differences in the response pattern during immunotherapy were observed. In patient 4 (nonresponder), an increase of CTLs was detected after the second vaccination, but thereafter the number of CTLs decreased even below baseline values corresponding with a clinical progress of the disease. This stays in accordance with the results of the proliferation assays in that particular patient, suggesting that an anticancer response has been induced. However, the disease in this patient in third relapse was very active and with a subsequent regimen of fludarabine and alemtuzumab only a partial remission could be achieved. On the opposite, in patient 8 with stable disease we observed a continuously increasing frequency of CTLs over the period of vaccination. Also in two of three patients with fibromodulin expression (but without RHAMM expression; patients 6 and 7, RS) we observed an increasing frequency of CTLs during vaccination. Studies by Gitelson et al. 51 demonstrated that in some B-CLL patients a population of tumor-specific T cells exists which were able to lyse autologous cancer cells. The aim of immunotherapy is to increase the number and activation status of TAA-specific T cells. Our data suggest that this might be In conclusion, the results of this study demonstrate that immunotherapy using autologous DCs pulsed with autologous B-CLL cell lysate was clinically feasible and safe. Our data suggest that the administration of mature DCs plus lysate consisting of several TAAs enhanced the antileukemic immunological and to some extent hematological responses in vivo. Additional methods of presenting TAAs by DCs such as transfection of mRNA encoding TAAs, as well as the use of further adjuvants such as cytosine-phosphate-guanine-rich oligodinucleotides or blockers of T-regulatory cells should be investigated in further clinical vaccination trials.
